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ABSTRACT In skeletal muscle, the L-type voltage-gated Ca21 channel (1,4-dihydropyridine receptor) serves as the voltage
sensor for excitation-contraction (EC) coupling. In this study, we examined the effects of Rem, a member of the RGK (Rem,
Rem2, Rad, Gem/Kir) family of Ras-related monomeric GTP-binding proteins, on the function of the skeletal muscle L-type
Ca21 channel. EC coupling was found to be weakened in myotubes expressing Rem tagged with enhanced yellow ﬂuorescent
protein (YFP-Rem), as assayed by electrically evoked contractions and myoplasmic Ca21 transients. This impaired EC coupling
was not a consequence of altered function of the type 1 ryanodine receptor, or of reduced Ca21 stores, since the application of
4-chloro-m-cresol, a direct type 1 ryanodine receptor activator, elicited myoplasmic Ca21 release in YFP-Rem-expressing
myotubes that was not distinguishable from that in control myotubes. However, YFP-Rem reduced the magnitude of L-type
Ca21 current by ;75% and produced a concomitant reduction in membrane-bound charge movements. Thus, our results
indicate that Rem negatively regulates skeletal muscle EC coupling by reducing the number of functional L-type Ca21 channels
in the plasma membrane.
INTRODUCTION
The skeletal muscle L-type Ca21 channel (1,4-dihydropyr-
idine receptor (DHPR)) serves as the voltage sensor for
excitation-contraction (EC) coupling (1). Conformational
changes in the DHPR in response to plasma membrane de-
polarization are conveyed to the ryanodine-sensitive Ca21
release channel (RyR1), resulting in efﬂux of Ca21 from the
stores of the sarcoplamsic reticulum (SR) and in activation of
the contractile machinery (2). Because communication be-
tween theDHPR andRyR1 is rapid and does not require Ca21
entry via the L-type channel itself (3–5), it is believed that
there is a physical interaction between the two proteins. This
view is supported by ultrastructural evidence demonstrating
that the tetradic arrangement of L-type channels within skel-
etal muscle triad junctions is altered by exposure to ryanodine
(6). Because the DHPR is a key protein in EC coupling,
modulation of its activity may have signiﬁcant consequences
for the frequency, strength, and duration ofmuscle contraction.
Members of the RGK (Rem, Rem2, Rad, Gem/Kir) family
of Ras-related monomeric GTP-binding proteins inhibit
high-voltage-activated (HVA) Ca21 channels via an inter-
action with Ca21 channel b subunit isoforms (7–16). Recent
evidence indicates that Ca21 channel a1 subunits and RGK
proteins have structurally distinct binding sites within the
conserved guanylate-kinase-like domain of b subunits and
that such interactions may support formation of a tripartite
complex (14,15). Several studies have established that over-
expression of an RGK family member ablates, or nearly
ablates, HVA Ca21 currents in a variety of preparations (7–
14,16–21). Moreover, intramembrane charge movements of
cardiac myocytes were reduced by viral overexpression of
Gem (17), indicating that this RGK protein either prevents
voltage-driven conformational changes necessary for chan-
nel gating or reduces the number of channel proteins in the
plasma membrane. Establishing which of these mechanisms
accounts for the inhibition of Ca21 channels by RGK pro-
teins is a matter of ongoing debate. Some biochemical and
morphological evidence suggests that the RGK-b subunit
interaction causes a reduction in the total number of channel
proteins in the plasma membrane (7,9,10,12,13,15,16).
However, binding of radiolabeled v-conotoxin GVIA to
heterologously-expressed N-type channels in tsA-201 ﬁbro-
blasts and surface biotinylation of native L-type channels in
HIT-T15 b-islet cells were both found to be unaltered by
exogenous expression of RGK proteins (11,14,19). More-
over, Rem2 affects gating kinetics of cloned a1C channels
heterologously-expressed in Xenopus laevis oocytes (21).
These latter ﬁndings point to a mechanism of action by which
RGKs may modulate HVA channels at the plasma membrane
by altering channel gating. Regardless of the mechanism,
overexpression of RGK family proteins negatively regulates
physiological processes dependent on the activity of HVA
Ca21 channels including myocardial function (16,17,20) and
secretion in pancreatic and neuroendocrine cells (7,11,12).
Rem is endogenously expressed in normal skeletal muscle
and Finlin et al. have reported that viral overexpression of
Rem inhibits myoplasmic Ca21 release in C2C12 myoblasts
in response to membrane depolarization (8). However, the
mechanism for this inhibition of EC coupling was not estab-
lished. One possibility is that overexpression of Rem impairs
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the formation of the junctional associations between the
plasma membrane and the SR that are required for EC cou-
pling. Although Finlin and colleagues (8) did not ﬁnd Rem-
induced morphological changes, other groups have reported
that overexpression of Rem or other RGK family members
causes pronouncedmorphological changes in a number of cell
types (9,10,13,18,22–25), including C2C12 myoblasts (9). A
second possibility is that Rem directly inhibits the function of
the DHPR as voltage sensor for EC coupling. A third possi-
bility is that Rem negatively modulates the EC coupling
machinery downstream of the voltage sensor by inhibiting
RyR1 or by reducing the SR Ca21 store. Here, we describe
experiments to distinguish these possibilities. We ﬁnd that
expression of YFP-Rem in normal myotubes reduces the
frequency of electrically evoked contractions, dampens
voltage-dependent Ca21 release from the SR, and decreases
the magnitude of L-type Ca21 currents and immobilization-
resistant charge movements, but does not affect Ca21 release
in response to the RyR activator 4-chloro-m-cresol. Thus,
YFP-Rem inhibits EC coupling in skeletal muscle by reduc-
ing the number of functionalDHPRs in the plasmamembrane.
MATERIALS AND METHODS
Construction of YFP-Rem
Rem (accession number U91601) tagged with hemagglutinin, was a kind gift
from Dr. D. A. Andres (University of Kentucky, Lexington, KY). To gen-
erate Rem tagged with enhanced yellow ﬂuorescent protein (YFP-Rem),
PCR-ampliﬁed YFP (Clontech, Palo Alto, CA) was cloned into pcDNA4.1
(Invitrogen, Carlsbad, CA) using KpnI and BamHI sites. Subsequently, full-
length Rem was ampliﬁed by PCR and cloned in-frame downstream of YFP
using BamHI and EcoRI sites. All PCR constructs were veriﬁed by sequencing.
Myotube culture and expression of cDNA
Primary cultures of normal (1/1 or 1/mdg on an outbred Black Swiss
background) and dyspedic (RyR1 null on C57BL/6 background) myotubes
were prepared from newborn mice, as described previously (26). Altogether,
myotubes from nine separate normal cultures and one dyspedic culture were
utilized in experiments. Two days after the change from plating to differ-
entiation medium, single nuclei were microinjected with YFP-Rem or
pEYFP-C1 (Clontech). The injection solution contained 5–100 ng/ml of
YFP-Rem cDNA or 10 ng/ml of YFP cDNA. In the initial stages of the study,
concentrations of YFP-Rem cDNA ranging from 5–100 ng/ml were assayed
by their ability to reduce L-type current. The effects on L-type current were
similar for each concentration tested (analysis of variance (ANOVA), p .
0.05). In the majority of experiments (including the measurement of both
Ca21 transients and charge movements), 10 ng/ml YFP-Rem cDNA was the
amount chosen to be used, because at this concentration, YFP-Rem could be
detected easily by ﬂuorescence without the potentially deleterious effects of
higher YFP-Rem expression levels. N-benzyl-P-toluene sulfonamide (BTS,
20 mM; S949760, Sigma, St. Louis, MO) was added to the culture medium
during microinjection to prevent contractions. Fluorescent myotubes were
used in experiments 2 days after microinjection.
Contractions
Electrically evoked contractions were elicited by 10-ms, 100-V stimuli
applied via an extracellular pipette that contained 150 mM NaCl (see
Papadopoulos et al. (27)). The myotubes were bathed in rodent Ringer’s
solution (in mM, 146 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and
11 glucose, pH 7.4, with NaOH). Contractions were assayed by the move-
ment of an identiﬁable portion of a myotube across the visual ﬁeld.
Measurement of intracellular Ca21 transients
Changes in intracellular Ca21 were recorded with Fluo-3 (No. F-3715,
Molecular Probes, Eugene, OR). The salt form of the dye was added to the
standard internal solution (see below) for a ﬁnal concentration of 200 nM.
After entry into the whole-cell conﬁguration, a waiting period of.5min was
used to allow the dye to diffuse into the cell interior. A 100 W mercury
illuminator and a set of ﬂuorescein ﬁlters were used to excite the dye present
in a small rectangular region of the voltage-clamped myotube. A computer-
controlled shutter was used to block illumination in the intervals between
50-ms test pulses. Fluorescence emission was measured by means of a
ﬂuorometer apparatus (Biomedical Instrumentation Group, University of
Pennsylvania, Philadelphia, PA). The average background ﬂuorescence was
quantiﬁed before bath immersion of the patch pipette. Fluorescence data are
expressed as DF/F, where DF represents the change in peak ﬂuorescence
from baseline during the test pulse and F is the ﬂuorescence immediately
before the test pulse minus the average background (non-Fluo-3) ﬂuores-
cence. Where applicable, the peak value of the ﬂuorescence change (DF/F)
for each test potential (V) was ﬁtted according to
ðDF=FÞ ¼ ðDF=FÞ
max
=ð11 expððVF  VÞ=kFÞÞ; (1)
where (DF/F)max is the maximal ﬂuorescence change, VF is the potential
causing half the maximal change in ﬂuorescence, and kF is a slope parameter.
Measurements of responses
to 4-chloro-m-cresol
Myotubes were washed with Ca21/Mg21-free Ringer’s (in mM, 146 NaCl, 5
KCl, 10 HEPES, 11 glucose, pH 7.4, with NaOH) twice and subsequently
loaded with 5 mM Fluo-3 AM (F-1242, Molecular Probes) dissolved in ro-
FIGURE 1 YFP-Rem inhibits skeletal mus-
cle EC coupling without affecting Ca21 release
in response to direct activation of RyR1. (A)
YFP-Rem reduces the fraction of myotubes
contracting in response to a 100-V, 10-ms
electrical stimulus. (B) Representative changes
in Fluo-3 AM ﬂuorescence in response to ap-
plication of 4-CmC (0.5 mM) elicited in a nor-
mal myotube (upper), a myotube expressing
YFP-Rem (middle), and a dyspedic myotube
(lower). Black arrows indicate time of 4-CmC
application. (C) Summary of myoplasmic Ca21
transients in response to 4-CmC (0.5 mM) for normal (black bar), YFP-Rem-injected (gray bar) normal, and dyspedic myotubes (white bar). Throughout, error
bars represent mean6 SE. For each group in A and C, the total number of myotubes tested is indicated above each bar.
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dent Ringer’s solution for 1 h. Myotubes were then washed three times in
rodent Ringer’s solution with gentle agitation. Fluo-3-AM-loaded myotubes
were then placed on the stage of a Nikon Diaphot inverted microscope and
viewed under 403 magniﬁcation. A 100 W mercury illuminator and a set of
ﬂuorescein ﬁlters were used to excite the Fluo-3 AM dye present in an iso-
lated myotube. To facilitate identiﬁcation of myotubes expressing YFP-Rem
in the presence of Fluo-3 AM, yellow ﬂuorescent myotubes were cytoplas-
mically injected with 1 mM sulforhodamine (S-1307, Molecular Probes)
before loading; myotubes expressing YFP-Rem were then identiﬁed by red
ﬂuorescence. Transients were elicited by application of a bolus of 4-chloro-
m-cresol (4-CmC) (C10570, Pfaltz and Bauer, Waterbury, CT) via an ex-
tracellular pipette placed near the myotube of interest. 4-CmC was dissolved
in EtOH to make a stock solution of 500 mM and was diluted in 150 NaCl to
the working concentration (0.5 mM) just before experiments. Fluorescence
emission was measured essentially as described above.
Measurement of L-type Ca21 currents
Pipettes were fabricated from borosilicate glass and had resistances of ;2.0
MV when ﬁlled with internal solution, which consisted of (mM) 140 Cs-as-
partate, 10 Cs2-EGTA, 5 MgCl2, and 10 HEPES, pH 7.4, with CsOH. The
standard external solution contained (mM) 145 TEA (tetraethylammonium)-
Cl, 10 CaCl2, 0.003 tetrodotoxin, and 10HEPES, pH7.4with TEA-OH. Linear
capacitative and leakage currents were determined by averaging the currents
elicited by eleven 30-mV hyperpolarizing pulses from a holding potential of
80 mV. Test currents were corrected for linear components of leak and ca-
pacitive current by digital scaling and subtraction of this average control cur-
rent. Electronic compensation was used to reduce the effective series resistance
(usually to ,1 MV) and the time constant for charging the linear cell capac-
itance (usually to,0.5 ms). Ionic currents were ﬁltered at 2 kHz and digitized
at 10 kHz. To measure macroscopic L-type current in isolation, a 1-s prepulse
to 20 mV followed by a 50-ms repolarization to 50 mV was administered
before the test pulse (prepulse protocol (28)) to inactivate T-type Ca21 chan-
nels. Cell capacitance was determined by integration of a transient from 80
mV to 70 mV using Clampex 8.0 and was used to normalize current am-
plitudes (pA/pF). Current/voltage (I/V) curves were ﬁtted using the equation
I ¼ Gmax  ðV  VrevÞ=ð11 expððV  V1=2Þ=kGÞÞ; (2)
where I is the current for the test potential, V; Vrev is the reversal potential;
Gmax is the maximum Ca
21 channel conductance, V1/2 is the half-maximal
activation potential; and kG is the slope factor. The activation phase of
macroscopic ionic currents was ﬁtted using the exponential function
IðtÞ ¼ Afastðexpðt=tfastÞÞ1Aslowðexpðt=tslowÞ1C; (3)
where I(t) is the current at time t after the depolarization; Afast and Aslow are
the steady-state current amplitudes of each component, with their respective
time constants of activation (tfast and tslow); andC represents the steady-state
peak current (see Avila and Dirksen (29)).
Measurement of charge movements
For measurement of intramembrane charge movements, ionic currents were
blocked by the addition of 0.5 mM CdCl2 1 0.1 mM LaCl3 to the standard
extracellular recording solution. All charge movements were corrected for
linear cell capacitance and leakage currents using a P/8 subtraction pro-
tocol. Filtering was at 2 kHz and digitization was at 20 kHz. Voltage-clamp
command pulses were exponentially rounded with a time constant of 50–500
ms and the prepulse protocol (see above (28)) was used to reduce the con-
tribution of gating currents from voltage-gated Na1 channels and T-type
Ca21 channels. The integral of the ON transient (Qon) for each test potential
(V) was ﬁtted according to
Qon ¼ Qmax=ð11 expððVQ  VÞ=kQÞÞ; (4)
whereQmax is the maximalQon, VQ is the potential causing movement of half
the maximal charge, and kQ is a slope parameter.
Analysis
To calculate Gmax/Q9 ratios, Gmax was calculated using Eq. 2 and Q9 was de-
rived by subtracting the average maximal charge movement of dysgenic my-
otubes (Qdys) from the average total Qmax, where Qdys ¼ 1.0 nC/mF ((30) and
Bannister and Beam, unpublished observations). Figures were made using
SigmaPlot (version 7.0, Systat Software, San Jose, CA). All data are presented
as mean6 SE. Statistical comparisons were by ANOVA or by unpaired, two-
tailed t-test (as appropriate), with p, 0.05 considered signiﬁcant.
RESULTS
YFP-Rem inhibits skeletal muscle EC coupling
To assay the effects of YFP-Rem expression on EC coupling,
myotube contractions were evaluated in response to electrical
FIGURE 2 YFP-Rem reduces voltage-dependent Ca21 release from the
SR. Recordings of myoplasmic Ca21 transients elicited by 50-ms depolar-
izations from 50 mV to the indicated test potentials are shown for a
nontransfected normal myotube (A) and a YFP-Rem-expressing myotube
(B). (C) Comparison of DF/F-V relationships for normal myotubes (d, n ¼
9) and myotubes expressing either YFP-Rem (s, n ¼ 8) or YFP (n, n ¼ 4).
Sigmoidal DF/F-V curves are plotted according to Eq. 1. The best-ﬁt
parameters for each plot are presented in Table 1.
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stimulation. Expression of YFP-Rem caused an ;50% re-
duction in the fraction of contracting myotubes (contractions
in 7 of 16myotubes; Fig. 1A) in comparison to nontransfected
normal and normal myotubes expressing unconjugated YFP
(contractions in 60 of 68 and 8 of 10 myotubes, respectively;
Fig. 1 A). To determine whether this reduction was a result of
an action of YFP-Rem on RyR1 or the SR Ca21 store, myo-
tubes were loaded with the Ca21 indicator Fluo-3 AM and
challenged with the RyR agonist 4-CmC. Robust responses
were observed in nontransfected, normal myotubes and in
YFP-Rem expressing myotubes, whereas no obvious re-
sponsewas seen in dyspedic (RyR1 null) myotubes (Fig. 1B).
On average, the responses to 4-CmC (0.5 mM) of control and
YFP-REM-expressing myotubes (2.0 6 0.9 DF/F, n ¼ 4 vs.
2.4 6 1.0 DF/F, n ¼ 5, respectively) were not signiﬁcantly
different (p ¼ 0.796; Fig. 1 C). In control experiments, dys-
pedic myotubes responded negligibly to 0.5 mM 4-CmC
(0.2 6 0.1 DF/F, n ¼ 5; Fig. 1 C). These data indicate that
YFP-Rem does not cause depletion of SR Ca21 stores or in-
hibit the ability of RyR1 to release Ca21 from the SR.
YFP-Rem inhibits voltage-dependent Ca21
release from the SR
Toobtainmore precise information regarding the inhibition of
EC coupling by YFP-Rem, we measured intracellular Ca21
transients in the whole-cell patch-clamp conﬁguration. As
shown in Fig. 2 A, nontransfected normal myotubes produced
robust Ca21 transients with an amplitude that had a sigmoidal
dependence on test potential (Fig. 2 C) and a maximum (DF/
F)max of 0.466 0.08 (n¼ 9).Myotubes expressingYFP-Rem
yielded Ca21 transients that were considerably smaller (Fig.
2 B), with a (DF/F)max of 0.146 0.11 (n¼ 8, p, 0.05). Only
one of the eight YFP-Rem-expressing myotubes examined
had sufﬁciently large Ca21 transients to analyze voltage de-
pendence, which appeared to be little affected (this cell
dominated the average data illustrated in Fig. 2 C). In control
experiments, expression of unconjugated YFP had no sig-
niﬁcant effect on either the magnitude or voltage dependence
of Ca21 transients relative to nontransfected normal myo-
tubes (Fig. 2 C and Table 1).
YFP-Rem reduces skeletal muscle L-type
Ca21 currents
Whole-cell patch-clamping was employed to test directly
whether Rem affects skeletal muscle L-type Ca21 currents
mediated by the DHPR. Normal myotubes produced large,
TABLE 1 YFP-Rem inhibits EC coupling
DF/F-V
DF/Fmax (DF/F) VF (mV) kF (mV)
Contracting cells/
number tested
Normal 0.46 6 0.08 (9) 6.9 6 1.2 6.4 6 0.5 60/68
Normal 1
YFP-Rem
0.14 (8) 8.4 6.8 7/16
Normal 1
YFP
0.63 6 0.25 (4) 4.3 6 0.9 6.5 6 0.3 8/10
DF/F-V relationships were ﬁtted using Eq. 1. For untransfected normal
myotubes and myotubes expressing YFP, data represent the average of the
ﬁts for each individual experiment (numbers in parentheses represent the
number of myotubes tested) and are given as mean 6 SE. Because seven of
eight experiments with myotubes expressing YFP-Rem were difﬁcult to ﬁt
with Eq. 1, the DF/F-V relationship is given as the ﬁt of the average data.
FIGURE 3 YFP-Rem reduces skeletal muscle L-type Ca21 current. Re-
cordings of L-type Ca21 currents elicited by 200-ms depolarizations from
50 mV to the indicated test potentials are shown for a normal, control
myotube (A) or a normalmyotubeexpressingYFP-Rem(B). (C)Comparisonof
I/V relationships for normal, control myotubes (d, n¼ 21), normal myotubes
expressing YFP-Rem (s, n ¼ 15), and normal myotubes expressing uncon-
jugated YFP (D, n ¼ 6). Currents were evoked at 0.1 Hz by test potentials
ranging from 20 mV through 180 mV in 10-mV increments, following a
prepulse protocol (28). The YFP-Rem I/V relationship represents pooled data
frommyotubes injected with 5, 10, 20, 50, and 100 ng/ml YFP-Rem cDNA; no
signiﬁcant difference in peak current density was found between these groups
(p . 0.05, ANOVA). The smooth curves are plotted according to Eq. 2. The
best ﬁt parameters for each plot are presented in Table 2.
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slowly activating L-type currents (10.4 6 0.9 pA/pF, n ¼
21; Fig. 3A). By comparison, L-type currentswere reduced by
73% in normal myotubes expressing YFP-Rem (2.8 6 0.5
pA/pF, n¼ 15, p, 106; Fig. 3 B). YFP-Rem caused a small
rightward shift in the voltage dependence of activation (V1/2¼
19.06 1.0 mV vs. 24.16 1.2 mV, for normal and YFP-Rem
currents, respectively, p¼ 0.003), but did not alter the kinetics
of activation (see Table 3). In control experiments, expression
of unconjugated YFP had no effect on either the voltage de-
pendence (V1/2¼ 20.36 1.4 mV, p. 0.05) or the magnitude
of L-type current (12.5 6 2.0 pA/pF, n ¼ 6, p . 0.05)
relative to nontransfected normal myotubes (Fig. 3 C and
Table 2).
YFP-Rem reduces skeletal muscle
charge movement
To determinewhether the reduction in L-type current byYFP-
Rem was a consequence of a reduced number of functional
DHPRs in the plasma membrane, immobilization-resistant
charge movements were measured. Charge movements in
YFP-Rem-expressing myotubes were reduced by 48% rela-
tive to normal, control myotubes (Qmax ¼ 2.5 6 0.4 nC/mF,
n¼ 7 vs. 4.86 0.5 nC/mF; n¼ 7, respectively; p¼ 0.004; Fig.
3, A–C). Under the assumption that theseQmax values include
a component unrelated to the DHPR (Qdys¼ 1.0 nC/mF) ((30)
and Bannister and Beam, unpublished observations), the ratio
of L-type conductance (Gmax) to charge (Q9 ¼ Qmax  Qdys)
was nearly identical in control and YFP-Rem-expressing
myotubes (63 vs. 61 nS/pC, respectively; Table 2). Thus, the
reduction in L-type current resulting from expression of YFP-
Rem can be accounted for by the decrease in functional
DHPRs.
DISCUSSION
The aim of this study was to determine the mechanism by
whichRem, anRGK familyGTP-binding protein, inhibits EC
coupling in skeletal muscle.We found that YFP-Rem reduces
the fraction of myotubes displaying electrically evoked con-
tractions and attenuates voltage-dependent myoplasmic Ca21
transients (Figs. 1 A and 2), consistent with the ﬁnding of
Finlin et al. that virally overexpressed Rem inhibits KCl-in-
duced myoplasmic Ca21 responses (8). Moreover, we found
that this impairment of EC coupling was not a consequence of
a reduced SR Ca21 store or of direct inhibition of RyR1 (Fig.
1, B and C). Instead, it appears that Rem inhibits EC coupling
by reducing the number of functional DHPRs, since both
L-type Ca21 currents and membrane charge movements
were reduced substantially inmyotubes expressingYFP-Rem
(Figs. 3 and 4, respectively). This is the ﬁrst demonstration
that skeletal muscle L-type (a1S-mediated) currents can be
modulated by an RGK family member. On average, the
skeletal muscle L-type channel was not inhibited by Rem to
the extent that has been observed for other L-type channels in
native and heterologous systems (8,13,14,20,21).
Recent evidence indicates that RGK proteins interact with
b subunits via a subdomain of the highly conserved guanylate
kinase domain that is distinct from the subdomain that binds
the I-II loop of the a1 subunit (14,15). This ﬁnding is partic-
ularly important when considered in the context of skeletal
TABLE 2 L-type Ca21 current conductance and charge movement
G-V Q-V
Gmax (nS/nF) V1/2 (mV) kG (mV) Qmax (nC/mF) VQ (mV) kQ (mV) Gmax/Q9 (nS/pC)
Uninjected normal 238 6 16 (21) 19.0 6 1.0 4.6 6 0.3 4.8 6 0.5 (7) 3.3 6 0.5 9.3 6 0.8 63
Normal 1 YFP-Rem 92 6 10z (12) 24.1 6 1.2* 5.3 6 0.8 2.7 6 0.5y (7) 3.4 6 3.4 8.6 6 1.3 61
Normal 1 YFP 268 6 39 (6) 20.3 6 1.4 4.7 6 0.7 ND ND
Data are given as mean 6 SE; numbers in parentheses indicate the number of myotubes tested. Three myotubes expressing YFP-Rem had no appreciable
L-type current and, for that reason, were not able to be ﬁt by Eq. 2; these cells were included in the calculation of total current density (see Results), but were
omitted from the data presented in Table 2. Gmax was calculated according to Eq. 2, whereas the Q9 was derived by subtracting the average maximal charge
movement of dysgenic myotubes (Qdys) from the average total Qmax, where Qdys ¼ 1.0 nC/mF (see Bannister and Beam (30)). Symbols indicate signiﬁcant
differences (*p , 0.05; yp , 0.005; zp , 106) compared to normal myotubes by t-test. I/V and Q/V curves are plotted according to Eqs. 2 and 4,
respectively (see Materials and Methods). For all the data given, the calculated average voltage error was ,5 mV.
TABLE 3 L-type Ca21 current activation ﬁt parameters
Islow Ifast
tslow (ms) Aslow (pA/pF) Fraction (%) tfast (ms) Afast (pA/pF) Fraction (%)
Normal 94.1 6 7.7 (11) 10.0 6 1.1 87 6 3 8.6 6 1.1 1.6 6 0.4 13 6 3
Normal 1 YFP-Rem 108.8 6 9.0 (6) 3.3 6 0.7* 84 6 4 6.1 6 0.3 0.5 6 0.1 16 6 4
Activation was ﬁtted with a double exponential function (Eq. 3) yielding time constants tfast and tslow with absolute or fractional amplitudes Aslow and Afast
(see Avila and Dirksen (29)). Data are given as mean 6 SE; numbers in parentheses indicate the number of myotubes tested. The asterisk indicates a
signiﬁcant difference (p , 0.001). The analysis of activation kinetics excluded cells with very small currents and cells in which tail current decay was
obviously not monoexponential.
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muscle, because the b1a isoform is required for skeletal-type
EC coupling (31–37). The b1-null zebraﬁsh mutant relaxed
lacks the characteristic arrays of DHPR tetrads typically ob-
served in freeze-fracture replicas of normal skeletal muscle,
indicating that b1a is important for the linkage of DHPRs to
RyR1 (37). However, the reduced number of functional
DHPRs that are present in YFP-Rem-expressing myotubes
appears to be normally linked toRyR1, as indicated both by an
unaltered Gmax/Q9 ratio (Table 2) and normal activation ki-
netics (Table 3), both of which are substantially changed
when skeletal DHPRs are not coupled to RyR1 (29,38,39).
Measurement of immobilization-resistant charge move-
ments indicated that YFP-Rem reduced the total number of
functional a1S-DHPRs in the plasma membrane (Fig. 3 and
Table 2). Our data do not allow us to distinguish whether this
reduction is a consequence of decreased channel insertion/
increased channel internalization (7,9,10,12,13,15,16) or of
the ability of Rem to lock the channel in a nongating state
(11,14,19,20). A similar reduction in gating charge move-
ment, associated with a1C-DHPRs, has been observed in
ventricular myocytes after viral expression of Gem (17). In
contrast to the observed reduction in gating charge after
maintained expression of RGK proteins, recent work indi-
cates that acutely applied Rem can inhibit L-type Ca21 cur-
rents via a1C-DHPRs expressed in HEK293 cells, without
reducing gating charge movement (40). Possibly, Rem has
both acute and chronic effects, such that a rapid inhibition of
Ca21 current is followed by a slower reduction in the number
of functional channels in the plasma membrane.
It is clear that an important goal of future studies will be to
resolve the mechanisms whereby RGK proteins inhibit
voltage-gated Ca21 channels. Muscle cells would appear to
offer several advantages for such studies. For example, be-
cause they are concentrated in discrete foci (27,30,41),
membrane-associated, ﬂuorescently-tagged L-type channels
in myotubes can be identiﬁed with less ambiguity than the
more diffusely distributed channels typical of cultured neu-
rons or heterologously expressed channels. Thus, in myo-
tubes it should be possible to determine whether YFP-Rem
targets to channels already present in the plasma membrane
and whether this targeting depends on the isoforms of the
a1 and b subunits. Similarly, it will be of interest to determine
whether the subcellular targeting of YFP-Rem is altered in
myotubes lacking b subunits and whether exogenous ex-
pression of Rem alters the tetradic arrangement of DHPRs as
seen with freeze-fracture electron microscopy.
In summary, we have shown that the RGK GTP-binding
protein Rem inhibits EC coupling in skeletal muscle as a
consequence of reducing the number of functional DHPRs.
In addition to inhibition of EC coupling, this reduction in
functional DHPRs implies that Rem may modulate other
physiological processes in muscle cells that are dependent
on voltage-driven conformational changes of the DHPR, in-
cluding excitation-transcription coupling and excitation-
coupled Ca21 entry (42,43).
We thank Drs. N. M. Lorenzon, A. M. Payne, and D. C. Sheridan, and
Mr. J. D. Ohrtman for insightful discussions.
This work was supported in part by National Institutes of Health grants
NS24444 and AR44750 (to K.G.B.). R.A.B. was supported by a develop-
mental grant from the Muscular Dystrophy Association (MDA4155).
REFERENCES
1. Tanabe, T., K. G. Beam, J. A. Powell, and S. Numa. 1988. Restoration
of excitation-contraction coupling and slow calcium current in dys-
FIGURE 4 YFP-Rem reduces the number of functional L-type Ca21
channels (DHPRs) in the plasma membrane. Recordings of immobilization-
resistant charge movements elicited by 20-ms depolarizations from50 mV
to 30 mV, 10 mV, 110 mV, and 130 mV are shown for a normal,
control myotube (A) or a normal myotube expressing YFP-Rem (B). (C)
Comparison of Q-V relationships for normal, control myotubes (d, n ¼ 7)
and normal myotubes expressing YFP-Rem (s, n ¼ 7). Charge movements
were evoked at 0.1 Hz by test potentials ranging from40 mV through160
mV in 10-mV increments, following a prepulse protocol (28). Sigmoidal
Q-V curves are plotted according to Eq. 4. The best-ﬁt parameters for each
plot are presented in Table 2.
2636 Bannister et al.
Biophysical Journal 94(7) 2631–2638
genic muscle by dihydropyridine receptor complementary DNA. Na-
ture. 336:134–139.
2. Beam, K. G., and P. Horowicz. 2004. Excitation-contraction coupling
in skeletal muscle. In Myology. A. G. Engel and C. Franzini-
Armstrong, editors. McGraw-Hill, New York. 257–280.
3. Armstrong, C. M., F. M. Bezanilla, and P. Horowicz. 1972. Twitches
in the presence of ethylene glycol bis(-aminoethyl ether)-N,N9-tetraacetic
acid. Biochim. Biophys. Acta. 267:605–608.
4. Tanabe, T., K. G. Beam, B. A. Adams, T. Niidome, and S. Numa.
1990. Regions of the skeletal muscle dihydropyridine receptor critical
for excitation-contraction coupling. Nature. 346:567–569.
5. Dirksen, R. T., and K. G. Beam. 1999. Role of calcium permeation in
dihydropyridine receptor function. Insights into channel gating and
excitation-contraction coupling. J. Gen. Physiol. 114:393–403.
6. Paolini, C., J. D. Fessenden, I. N. Pessah, and C. Franzini-Armstrong.
2004. Evidence for conformational coupling between two calcium
channels. Proc. Natl. Acad. Sci. USA. 101:12748–12752.
7. Be´guin, P., K. Nagashima, T. Gonol, T. Shibasaki, K. Takahashi, N.
Ozaki, K. Geering, T. Iwanaga, and S. Seino. 2001. Regulation of Ca21
channel expression at the cell surface by the small G-protein kir/Gem.
Nature. 411:701–706.
8. Finlin, B. S., S. M. Crump, J. Satin, and D. A. Andres. 2003.
Regulation of voltage-gated calcium channel activity by the Rem and
Rad GTPases. Proc. Natl. Acad. Sci. USA. 100:14469–14474.
9. Be´guin, P., R. N. Mahalakshmi, K. Nagashima, D. H. K. Cher, N.
Kuwamura, Y. Yamada, Y. Seino, and W. Hunziker. 2005. Roles of
14-3-3 and calmodulin binding in subcellular localization and function
of the small G-protein Rem2. Biochem. J. 390:67–75.
10. Be´guin, P., R. N. Mahalakshmi, K. Nagashima, D. H. K. Cher, A.
Takahashi, Y. Yamada, Y. Seino, and W. Hunziker. 2005. 14-3-3 and
calmodulin control subcellular distribution of Kir/Gem and its regula-
tion of cell shape and calcium channel activity. J. Cell Sci. 118:1923–
1934.
11. Finlin, B. S., S. M. Crump, R. N. Correll, S. O¨zcan, J. Satin, and D. A.
Andres. 2005. Regulation of L-type Ca21 channel activity and insulin
secretion by the Rem2 GTPase. J. Biol. Chem. 280:41864–41871.
12. Sasaki, T., T. Shibasaki, P. Be´guin, K. Nagashima, M. Miyazaki, and
S. Seino. 2005. Direct inhibition of the interaction between a-interac-
tion domain and b-interaction domain of voltage-dependent Ca21
channels by Gem. J. Biol. Chem. 280:9308–9312.
13. Be´guin, P., R. N. Mahalakshmi, K. Nagashima, D. H. K. Cher, H.
Ikeda, Y. Yamada, Y. Seino, and W. Hunziker. 2006. Nuclear
sequestration of b-subuits by Rad and Rem is controlled by 14-3-3
and calmodulin and reveals a novel mechanism for Ca21 channel
regulation. J. Mol. Biol. 355:34–46.
14. Finlin, B. S., R. N. Correll, C. Pang, S. M. Crump, J. Satin, and D. A.
Andres. 2006. Analysis of the complex between Ca21 channel
b-subunit and the Rem GTPases. J. Biol. Chem. 281:23557–23566.
15. Be´guin, P., Y. J. Ng, C. Krause, R. N. Mahalakshmi, M. Y. Ng, and W.
Hunziker. 2007. RGK small GTP-binding proteins interact with the
nucleotide kinase domain of Ca21 channel b-subunits via an uncom-
mon effector-binding domain. J. Biol. Chem. 282:11509–11520.
16. Yada, H., M. Murata, K. Shimoda, S. Yuasa, H. Kawaguchi, M. Ieda,
T. Adachi, S. Ogawa, and K. Fukuda. 2007. Dominant negative
suppression of Rad leads to QT prolongation and causes ventricular
arrhythmias via modulation of L-type Ca21 channels in the heart. Circ.
Res. 101:69–77.
17. Murata, M., E. Cingolani, A. D. McDonald, K. Donahue, and E.
Marba´n. 2004. Creation of a genetic calcium channel blocker by
targeted Gem gene transfer in the heart. Circ. Res. 95:398–405.
18. Ward, Y., B. Spinelli, M. J. Quon, H. Chen, S. R. Ikeda, and K. Kelly.
2004. Phosporylation of critical serine residues in Gem separates
cytoskeletal reorganization from down-regulation of calcium channel
activity. Mol. Cell. Biol. 24:651–661.
19. Chen, H., H. L. Puhl, S.-L. Niu, D. C. Mitchell, and S. R. Ikeda. 2005.
Expression of Rem2, an RGK family small GTPase, reduces N-type
calcium current without affecting channel surface density. J. Neurosci.
25:9762–9772.
20. Crump, S. M., R. N. Correll, E. A. Schroder, W. C. Lester, B. S. Finlin,
J. Satin, and D. A. Andres. 2006. L-type calcium channel a-subunit
and protein kinase inhibitors modulate Rem-mediated regulation of
current. Am. J. Physiol. 291:H1959–H1971.
21. Seu, L., and G. S. Pitt. 2006. Dose-dependent and isoform-speciﬁc
modulation of Ca21 channels by RGK GTPases. J. Gen. Physiol. 128:
605–613.
22. Pan, J. Y., W. E. Fieles, A. M. White, M. M. Egerton, and D. S.
Silberstein. 2000. Ges, a human GTPase of the Rad/Gem/Kir family,
promotes endothelial cell sprouting and cytoskeletal reorganization.
J. Cell Biol. 149:1107–1116.
23. Leone, A., N. Mitsiades, Y. Ward, B. Spinelli, V. Poulaki, M. Tsokos,
and K. Kelly. 2001. The Gem GTP-binding protein promotes morpho-
logical differentiation in neuroblastoma. Oncogene. 20:3217–3225.
24. Piddini, E., J. A. Schmid, R. de Martin, and C. G. Dotti. 2001. The
Ras-like GTPase Gem is involved in cell shape remodeling and inter-
acts with the novel kinesin-like protein KIF9. EMBO J. 20:4076–4087.
25. Ward, Y., S. F. Yap, V. Ravichandran, F. Matsumura, M. Ito, B.
Spinelli, and K. Kelly. 2002. The GTP binding proteins Gem and Rad
are negative regulators of the Rho-Rho kinase pathway. J. Cell Biol.
157:291–302.
26. Beam, K. G., and C. Franzini-Armstrong. 1997. Functional and
structural approaches to the study of excitation-contraction coupling.
Methods Cell Biol. 52:283–306.
27. Papadopoulos, S., V. Leuranguer, R. A. Bannister, and K. G. Beam.
2004. Mapping sites of potential proximity between the DHPR and
RyR1 in muscle using a CFP-YFP tandem as a FRET probe. J. Biol.
Chem. 279:44046–44056.
28. Adams, B. A., T. Tanabe, A. Mikami, S. Numa, and K. G. Beam. 1990.
Intramembrane charge movement restored in dysgenic skeletal muscle
by injection of dihydropyridine receptor cDNAs. Nature. 346:569–572.
29. Avila, G., and R. T. Dirksen. 2000. Functional impact of the ryanodine
receptor on the skeletal muscle L-type Ca21 channel. J. Gen. Physiol.
115:467–480.
30. Bannister, R. A., and K. G. Beam. 2005. The a1S N-terminus is not
essential for bi-directional coupling with RyR1. Biochem. Biophys.
Res. Commun. 336:134–141.
31. Gregg, R. G., A. Messing, C. Strube, M. Beurg, R. Moss, M. Behan, C.
Sukhareva, S. Haynes, J. A. Powell, and R. Coronado. 1996. Absence
of the b1a subunit (cchb1) of the skeletal muscle dihydropyridine
receptor alters expression of the a1 subunit and eliminates excitation-
contraction coupling. Proc. Natl. Acad. Sci. USA. 93:13961–13966.
32. Strube, C., M. Beurg, C. Sukhareva, C. A. Ahern, J. A. Powell, P. A.
Powers, R. G. Gregg, and R. Coronado. 1996. Reduced Ca21 current,
charge movement and absence of Ca21 transients in skeletal muscle
deﬁcient in dihydorpyridine receptor b1 subunit. Biophys. J. 75:2531–
2543.
33. Beurg, M., C. A. Ahern, P. Vallejo, M. W. Conklin, P. A. Powers,
R. G. Gregg, and R. Coronado. 1999. Involvement of the carboxy-
terminus region of the dihydropyridine receptor b1a subunit in
excitation-contraction coupling of skeletal muscle. Biophys. J. 77:
2953–2967.
34. Sheridan, D. C., L. Carbonneau, C. A. Ahern, P. Nataraj, and
R. Coronado. 2003. Ca21-dependent excitation-contraction coupling
triggered by the heterologous cardiac/brain b2a-subunit in skeletal
muscle. Biophys. J. 85:3739–3757.
35. Sheridan, D. C., W. Cheng, C. A. Ahern, L. Mortensen, D. Alsammarae,
P. Vallejo, and R. Coronado. 2003. Truncation of the carboxyl ter-
minus of the dihydropyridine receptor b1a subunit promotes Ca
21
dependent excitation-contraction coupling in skeletal myotubes. Bio-
phys. J. 84:220–237.
36. Sheridan, D. C., W. Cheng, L. Carbonneau, C. A. Ahern, and R.
Coronado. 2004. Involvement of a heptad repeat in the carboxyl
terminus of the dihydropyridine receptor b1a subunit in the mechanism
Rem Inhibits the Skeletal Muscle DHPR 2637
Biophysical Journal 94(7) 2631–2638
of excitation-contraction coupling in skeletal muscle. Biophys. J. 87:
929–942.
37. Schredelseker, J., V. Di Biase, G. J. Obermaier, E. T. Felder, B. E.
Flucher, C. Franzini-Armstrong, and M. Grabner. 2005. The b1a
subunit is essential for the assembly of dihydropyridine-receptor arrays
in skeletal muscle tetrad formation. Proc. Natl. Acad. Sci. USA.
102:17219–17224.
38. Nakai, J., R. T. Dirksen, H. T. Nguyen, I. N. Pessah, K. G. Beam,
and P. D. Allen. 1996. Enhanced dihydropyridine receptor channel
activity in the presence of ryanodine receptor. Nature. 380:
72–75.
39. Sheridan, D. C., H. Takekura, C. Franzini-Armstrong, K. G. Beam,
P. D. Allen, and C. F. Perez. 2006. Bi-directional signaling between
calcium channels of skeletal muscle requires, multiple, direct and
indirect interactions. Proc. Natl. Acad. Sci. USA. 103:19760–
19765.
40. Suhail, Y., and H. M. Colecraft. 2007. GEMIICCs: genetically encoded
molecules for inducibly inactivating CaV channels. Biophys. J., 92:
354a. (Abstr.)
41. Grabner, M., R. T. Dirksen, and K. G. Beam. 1998. Tagging with green
ﬂuorescent protein reveals a distinct subcellular distribution of L-type
and non-L-type Ca21 channels expressed in dysgenic myotubes. Proc.
Natl. Acad. Sci. USA. 95:1903–1908.
42. Cherednichenko, G., A. M. Hurne, J. D. Fessenden, E. H. Lee, P. D.
Allen, K. G. Beam, and I. N. Pessah. 2004. Conformational activation
of Ca21 entry by depolarization of skeletal myotubes. Proc. Natl. Acad.
Sci. USA. 101:15793–15798.
43. Hurne, A. M., J. J. O’Brien, D. Wingrove, G. Cherednichenko, P. D.
Allen, K. G. Beam, and I. N. Pessah. 2005. Ryanodine receptor type I
(RyR1) mutations C4958S and C4961S reveal excitation-coupled
calcium entry (ECCE) is independent of sarcoplasmic reticulum store
depletion. J. Biol. Chem. 280:36994–37004.
2638 Bannister et al.
Biophysical Journal 94(7) 2631–2638
